References

Modulating glycolysis to improve cancer therapy

10.3390/ijms24032606 · 2023 · External reference

Targeting the Warburg effect in cancer: where do we stand?

10.3390/ijms25063142 · 2024 · External reference

Targeting cancer metabolism in the era of precision oncology

10.1038/s41573-021-00339-6 · 2022 · External reference

Targeting energy metabolism in cancer treatment

10.3390/ijms23105572 · 2022 · External reference

Targeting mitochondrial metabolism for precision medicine in cancer

10.1038/s41418-022-01022-y · 2022 · External reference

Signaling pathways in cancer metabolism: mechanisms and therapeutic targets

10.1038/s41392-023-01442-3 · 2023 · External reference

Emerging therapies in cancer metabolism

10.1016/j.cmet.2023.07.006 · 2023 · External reference

Glutaminase inhibition as potential cancer therapeutics: current status and future applications

10.1080/14756366.2023.2290911 · 2024 · External reference

Targeting glutamine metabolism as a therapeutic strategy for cancer

10.1038/s12276-023-00971-9 · 2023 · External reference

Amino acid metabolism in tumor biology and therapy

10.1038/s41419-024-06435-w · 2024 · External reference

Glutaminase - a potential target for cancer treatment

10.37796/2211-8039.1445 · 2024 · External reference

Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress

10.1182/bloodadvances.2023010964 · 2023 · External reference

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

10.3389/fonc.2023.1161254 · 2023 · External reference

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes

10.18632/oncotarget.12944 · 2016 · External reference

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN

10.1182/bloodadvances.2023010950 · 2024 · External reference

Emerging role of functional magnetic resonance spectroscopy (MRS) to monitor response to kinase inhibitors in cancer

2024 · External reference

Frontline managment of mantle cell lymphoma

10.1182/blood.2023022352 · 2025 · External reference

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond

10.1080/10428194.2023.2264430 · 2024 · External reference

Treatment of relapsed/refractory MCL

10.1182/blood.2023022353 · 2025 · External reference

B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity

10.1038/s41586-021-04082-1 · 2021 · External reference

GABAergic signaling by cells of the immune system: more the rule than the exception

10.1007/s00018-021-03881-z · 2021 · External reference

B cells secrete GABA, which provokes a pro-tumor immune microenvironment

10.1016/j.ccell.2021.12.007 · 2022 · External reference

Metabolic detection of Bruton's tyrosine kinase inhibition in mantle cell lymphoma cells

10.1158/1541-7786.mcr-18-0256 · 2019 · External reference

Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition

10.1186/s12967-024-05371-9 · 2024 · External reference